Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochrome P450 3A (CYP3A) and may, therefore, pose a risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Eunjin, Carmanov, Eugeniu, Shi, Alan, Chung, Peter S., Rao, Adupa P., Forrester, Kevin, Beringer, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222456/
https://www.ncbi.nlm.nih.gov/pubmed/37242680
http://dx.doi.org/10.3390/pharmaceutics15051438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222456/
https://www.ncbi.nlm.nih.gov/pubmed/37242680
http://dx.doi.org/10.3390/pharmaceutics15051438

Ejemplares similares